DCML: Deep contrastive mutual learning for COVID-19 recognition.

COVID-19 is a form of disease triggered by a new strain of coronavirus. Automatic COVID-19 recognition using computer-aided methods is beneficial for speeding up diagnosis efficiency. Current researches usually focus on a deeper or wider neural network for COVID-19 recognition. And the implicit contrastive relationship between different samples has not been fully explored. To address these problems, we propose a novel model, called deep contrastive mutual learning (DCML), to diagnose COVID-19 more effectively. A multi-way data augmentation strategy based on Fast AutoAugment (FAA) was employed to enrich the original training dataset, which helps reduce the risk of overfitting. Then, we incorporated the popular contrastive learning idea into the conventional deep mutual learning (DML) framework to mine the relationship between diverse samples and created more discriminative image features through a new adaptive model fusion method. Experimental results on three public datasets demonstrate that the DCML model outperforms other state-of-the-art baselines. More importantly, DCML is easier to reproduce and relatively efficient, strengthening its high practicality.

Antiviral therapy for coronavirus disease 2019. / 2019å† çŠ¶ç— æ¯’ç— çš„æŠ—ç— æ¯’æ²»ç–—.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the outbreak of coronavirus disease 2019 in Wuhan City, China. The SARS-CoV-2 is genetically similar to the coronavirus derived from bat. The SARS-CoV-2, the SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV) all belong to beta coronavirus. Since the outbreak of the coronavirus disease 2019, effective antiviral drugs have become a hot issue in the world. Very little about SARS-CoV-2 is known and there is no precedent for treatment. The National Health Commission has repeatedly revised the diagnosis and treatment guide for the coronavirus disease 2019. The latest guide is "New Coronary Virus-Infected Pneumonia Diagnosis and Treatment Plan (Seventh Trial Version)"(short for Seventh Version of Diagnosis and Treatment Plan). But the use of antiviral drugs is still on trial and no rigorous clinical trials data is available. Hot anti-SARS-CoV-2 drugs include interferon α, ribavirin, lopinavir/ritonavir, chloroquine phosphate, abidol, as well as hydroxychloroquine sulfate and remdesivir. But the later 2 drugs aren't mentioned in the Seventh Version of Diagnosis and Treatment Plan.